STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on Nov 6, 2023.
For 4 years, STENOCARE has been working hard to reach and exceed the sales volumes of 2018 and 2019, its first two years of successful operation.
This announcement is made ahead of the Q3-22 report in order to share with the market the recent positive development in sales and the related updated guidance for 2023 and 2024. For more details, see graph in attachment to this press release.
Læs resten af meddelelsen i vedhæftning.
Stenocare har en betalt digital IR-aftale med ProInvestor.com
2023_11_06_STENOCARE_Updated_guida..
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on Nov 6, 2023.
For 4 years, STENOCARE has been working hard to reach and exceed the sales volumes of 2018 and 2019, its first two years of successful operation.
This announcement is made ahead of the Q3-22 report in order to share with the market the recent positive development in sales and the related updated guidance for 2023 and 2024. For more details, see graph in attachment to this press release.
Læs resten af meddelelsen i vedhæftning.
Stenocare har en betalt digital IR-aftale med ProInvestor.com
2023_11_06_STENOCARE_Updated_guida..
6/11 2023 15:16 ProInvestorNEWS 2
116570 STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE: One-off return of products from Norway
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation.
The information was provided by the contact person below for publication on Nov 6, 2023.
Return of products: On 28 October 2022, STENOCARE was able to proudly announce its access to the Norwegian market, making STENOCARE the first and only supplier of full spectrum oil based medical cannabis products in Norway. The initial projections for number of patients were based on historic pain treatment data in Norwegian pain centres. Then, during Q4, 2022, STENOCARE shipped products to its new local partner, Apotek 1, the leading distributor and pharmacy chain in Norway to supply these patients with their full spectrum medical cannabis oil products. However, it turned out that the management of the pain centres (hospitals) decided to hold back the budget for treatment with all cannabis-based products - which slowed down sales run rate and resulted in products expiring. Due to this situation in Norway, products worth DKK 2,1m have now been returned to STENOCARE
Læs hele meddelelsen i vedhæftning:
Stenocare har en betalt digital IR-aftale med ProInvestor.com2023_11_06_STENOCARE_financial_upd..
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE: One-off return of products from Norway
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation.
The information was provided by the contact person below for publication on Nov 6, 2023.
Return of products: On 28 October 2022, STENOCARE was able to proudly announce its access to the Norwegian market, making STENOCARE the first and only supplier of full spectrum oil based medical cannabis products in Norway. The initial projections for number of patients were based on historic pain treatment data in Norwegian pain centres. Then, during Q4, 2022, STENOCARE shipped products to its new local partner, Apotek 1, the leading distributor and pharmacy chain in Norway to supply these patients with their full spectrum medical cannabis oil products. However, it turned out that the management of the pain centres (hospitals) decided to hold back the budget for treatment with all cannabis-based products - which slowed down sales run rate and resulted in products expiring. Due to this situation in Norway, products worth DKK 2,1m have now been returned to STENOCARE
Læs hele meddelelsen i vedhæftning:
Stenocare har en betalt digital IR-aftale med ProInvestor.com
2023_11_06_STENOCARE_financial_upd..